Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
Publikation: Beitrag in Fachzeitschrift › Forschungsartikel › Beigetragen › Begutachtung
Beitragende
Abstract
BACKGROUND: The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain.
METHODS: Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response.
RESULTS: Three hundred twenty-two people with MS were included; 91.9% received an mRNA vaccine. Post-vaccination reactive IgG rates (IgG index > 1) were 40% for anti-CD20 (32/80 patients); 41% for sphingosine 1-phosphate receptor modulators (S1PRM, 16/39); and 100% for all other classes, including the no DMT group.
CONCLUSION: Anti-CD20 therapies and S1PRMs reduce IgG response to SARS-CoV-2 vaccination; IgG response is preserved with other DMTs.
Details
| Originalsprache | Englisch |
|---|---|
| Seiten (von - bis) | 1131-1137 |
| Seitenumfang | 7 |
| Fachzeitschrift | Multiple Sclerosis Journal |
| Jahrgang | 28 |
| Ausgabenummer | 7 |
| Frühes Online-Datum | 7 Jan. 2022 |
| Publikationsstatus | Veröffentlicht - Juni 2022 |
| Peer-Review-Status | Ja |
Externe IDs
| PubMedCentral | PMC9131404 |
|---|---|
| Scopus | 85122656213 |
| ORCID | /0000-0001-8799-8202/work/171553568 |
Schlagworte
Ziele für nachhaltige Entwicklung
Schlagwörter
- Antibodies, Viral, COVID-19 Vaccines, COVID-19/prevention & control, Humans, Immunity, Immunoglobulin G, Multiple Sclerosis/drug therapy, SARS-CoV-2, Technology, Vaccination, Vaccines, Synthetic, mRNA Vaccines